anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Objective methods for detecting and diagnosing bladder cancer (BLC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of a BLC-associated gene that discriminates between BLC cells and normal cells. The present invention further provides means for predicting and preventing bladder cancer metastasis using BLC-associated genes having unique altered expression patterns in bladder cancer cells with lymph-node metastasis. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of bladder cancer, methods of treating bladder cancer and method for vaccinating a subject against bladder cancer. In particular, the present application provides novel human genes C2093, B5860Ns and C6055s whose expression is markedly elevated in bladder cancers. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of bladder cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of bladder cancer.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. 

Carefully remove the gray plastic cap from the top of the vial by lifting it up from the edges with your fingers or by pushing the bottom edge of the cap upward using the top of your thumb. Remove only the gray plastic cap while leaving the aluminum metal ring and crimp seal around the gray rubber stopper in place. To facilitate the removal of medication from the vial, attach an 18-gauge needle and draw 3 mL of air into the syringe. Hold the needle at a 45° angle to the stopper with the bevel in the up orientation. Inject through the gray rubber stopper into the vial to create positive pressure within the vial chamber.

Withdraw 3 mL (750 mg) of AVEED solution from the vial. Expel excess air bubbles from the syringe. Replace the syringe needle used to draw up the solution from the vial with a new intramuscular needle and inject. Discard any unused portion in the vial.
Sudden unexpected infant death (SUID) is the leading cause of postneonatal infant mortality in the United States, with disproportionately high rates in Baltimore City and Baltimore County in Maryland. This Advocacy Case Study describes the collaboration between the City and County Child Fatality Review teams to decrease infant mortality. B'more for Healthy Babies, formed in 2009 by the Bureau of Maternal Child Health in Baltimore City with the goal of reducing infant mortality through policy change, service improvements, community mobilization, and behavior change has had a sustained effort to respond to SUID. Recognizing that infants born in Baltimore City often reside in Baltimore County (and vice versa), collaboration with Baltimore County has been essential to increasing B'more for Healthy Babies' scope, reach, and effectiveness. Public health messaging campaigns, creation, and dissemination of a "SLEEP SAFE" testimonial video, and Safe Sleep Summits have involved caregivers, healthcare providers, and community partners. Outcomes of this ongoing collaboration demonstrate a decrease in sleep-related infant mortality rates. Our findings also highlight the need for continued, real time monitoring of sleep-related infant mortality trends with a coordinated, multidisciplinary, and crossjurisdictional response. This initiative can serve as a model of cross-sector communication that can be replicated in other similar geographic locations to further reduce SUID.
Survivors of cardiac arrest at high risk of neurological deterioration. Participants will undergo placement of a Spencer Probe Depth Electrode and QFlow 500™ Perfusion Probe in addition to the institutional standard multimodal neurological monitoring.
Each canal was prepared using Reciproc Blue nickel titanium primary file 25/08 (VDW, Munich, Germany) driven by a Xsmart IQ motor (Dentsply, Maillefer, Ballaigues, Switzerland) according to the manufacturer's instructions. Continuous checking of the canal patency was done using size 10 handfile followed by irrigation with 3 mL room temperature 5.25% sodium hypochlorite using irriflex endodontic irrigation needle mounted on a 3mL syringe each time the rotary file was removed out of the canal. Once the instrumentation was done, the canal was irrigated with 5 mL of 17% ethylenediaminetetraacetic acid (EDTA) kept for 60 seconds and then flushed with 5 mL of saline. NaOCl was placed in the canal and PUA followed by intracanal heating was performed three times as described for group 1 (IHAN).
The Kinect based rehabilitation group received virtual reality therapy using Xbox Kinect-based games, in addition to complex decongestive physiotherapy. The intervention was led once per day, five days a week, over 8 weeks. All participants wearing multilayer bandage or compression stocking during training to avoid exacerbation of the lymphedema in the affected limb.
Enteral nutrition is the preferred route for the provision of nutritional support in most critical ill patients with functional gastrointestinal tract. Achieving early enteral nutrition (EN) in critically ill patients is associated with fewer major complications, reduced mortality and length of hospital stay, and significant cost savings. It is estimated that approximately 1.2 million feeding tubes are placed blindly each year in the United States alone. Despite the obvious advantages of the enteral tube feeding, inadvertent placement of Enteral Feeding Tube (EFT) into the airway is relatively common and can result in significant pulmonary injury including pneumothorax and pneumonia. Airway misplacement occurs in 1.2- 4 % of blind EFT insertions, with 0.2 to 1.2% of all the feeding tube placements cause pulmonary complications to patients. The gold standard for detecting inadvertent placement of a feeding tube in the lungs is radiography. However, because of its cost, possible delay of feedings while waiting for radiography, and risk for radiation exposure, clinicians continue to seek for alternative methods to confirm correct placement.

All the above mentioned, emphasizes the fact that safe and effective delivery of nasoenteral tube feedings requires assurance that the feeding tube tip is in a proper position. The ENVUE™ System is an electromagnetic tracking system which tracks the path of the feeding tube during placement. The benefit of the system when EFT is misdirected into the pulmonary system is a real-time visual tracing, which may prompt users to withdraw the tube and reinsert it.
Ypeginterferon alfa-2b,sc. Qw. 48 weeks.
Nanoparticles, such as liposomes etc., containing multiple reporter molecules, e.g. dyes, fluorophores, FRET pairs, semiconductor nanocrystals, fluorescent chelates, chelate complexes, coordination complexes, mass tags, Raman tags, lanthanides, enzymes, enzymatic substrates, etc., through a combination of multiple physical and/or chemical interactions are disclosed. The reporter molecules are associated with the nanoparticle in at least two different ways, i.e. through different mechanisms. The nanoparticle is targeted through a targeting agent such as an antibody, an antibody fragment, a nucleotide, a peptide, an aptamer, biotin, avidin, or a ligand. The nanoparticles are useful in bioassays or imaging where an analyte is to be detected by binding of the nanoparticle to the analyte and detection of a signal from the reporter molecules.
Injury of the anterior cruciate ligament (ACL) is one of the most common injuries of the knee. ACL reconstruction using auto- and allografts is still the gold-standard technique and widely used in the surgical treatment of ACL ruptures. Potential deficits in the affected leg are frequently evaluated using the limb symmetry index (LSI) calculated as performance affected side/performance unaffected side x 100. Several factors other than injury may influence single leg hop (SLH) distance and LSI such as sex, age, and muscle strength. This retrospective study aims at analysing demographics and clinical, functional and biomechanical outcomes in patients after ACL injury (conservative therapy and/or surgery) in patients of different ages and healthy controls. Demographics, as well as clinical, functional and biomechanical parameters were collected between 2019 and 2022 in two research projects approved by the Ethikkommission Nordwestschweiz (EKNZ 2019-00491, EKNZ 2019-01315, EKNZ 2020-00551)
Type 1 diabetes is commonly treated with the administration of insulin, either by multiple insulin injections or by a continuous supply of insulin through a wearable pump. Insulin therapy allows long-term survival in individuals with type 1 diabetes; however, it does not guarantee constant normal blood sugar control. Because of this, long-term type 1 diabetic survivors often develop vascular complications, such as diabetic retinopathy, an eye disease that can cause poor vision and blindness, and diabetic nephropathy, a kidney disease that can lead to kidney failure and thus kidney transplant. Some individuals with type 1 diabetes develop hypoglycemia unawareness, a life-threatening condition that is not easily treatable with medication and is characterized by reduced or absent warning signals for hypoglycemia. For such individuals, pancreas or pancreatic islet transplantation are possible treatment options. The purpose of this study is to assess the benefit of islet transplantation in type 1 diabetic kidney transplant recipients.

Participants in this study will be type I diabetics who have received a kidney transplant for ESRD.. If subjects have not received ITT in the 12 months prior to enrollment, they must undergo a period of standardized diabetes care by an experienced diabetologist at the transplant center using the current ADA's standards of medical care in diabetes. Throughout the study, all participants will remain on the immunosuppressive therapy intended for their kidney. Participants will receive up to three separate islet transplants and a regimen of immunosuppressive medications consisting of antithymocyte globulin (ATG) and etanercept. They will begin receiving ATG 2 days prior to transplant and will continue to receive ATG until Day 2 post-transplant. Etanercept will be given on the day of transplant and on Days 3, 7, and 10 post-transplant.

Transplantations will involve an inpatient hospital stay and infusion of islets into a branch of the portal vein. Participants who do not achieve or maintain insulin independence by Day 30 post-transplant will be considered for a second islet transplant. Participants who remain dependent on insulin for longer than 30 days after the second transplant and who show partial graft function will be considered for a third islet transplant. Daclizumab will be used in place of ATG for the second and third transplants, if they are necessary. Participants who do not meet the criteria for a subsequent transplant will enter a reduced follow-up period.

There will be approximately 15 study visits. A physical exam, review of adverse events, and blood collection will occur at most visits. A chest x-ray, abdominal ultrasound, electrocardiogram, quality of life questionnaires, and urine collection will occur at some visits. Participants will also test their own blood glucose levels throughout the study. A 36-month follow-up period will take place after the participant's last transplant, consisting of 8 additional visits.
PURPOSE:To obtain a liquid preparation having high concentration capable of clinically easily administering aureobasidin A (R106-I) useful as an antibacterial agent in the amount needed for treatment. CONSTITUTION:This liquid preparation having high concentration of R106-I contains R106-I, a polyoxiethylene castor oil-based activator and ethanol as essential components, preferably >=65 pts.wt. of the polyoxiethylene castor oil-based activator and >=30 pts.wt of ethanol based on 100 pts.wt. of R106-I, wherein the concentration of R106-I is 20-40w/w% base on the total of the preparation. This preparation is excellent in oral absorbability. Further, a capsule preparation obtained by filling this liquid preparation having high concentration in a gelatin hard capsule containing polyethylene glycol (PEG), is an excellent preparation free from breakage of the capsule and leakage of the contained liquid.
An ultrasonic diagnostic apparatus is provided. The purpose of the present invention is to appropriately set the acoustic properties of a push wave for measuring elastic properties according to the physical properties of living tissue. A push wave transmitting unit (14) transmits a push wave to a living tissue of a subject (50). A tracking wave transmitting/receiving unit (16) transmits a tracking wave to the living tissue and receives the reflected ultrasonic wave reflected by the living tissue. An elasticity analysis unit (30) measures the propagation velocity of a shear wave generated by a push wave in a living tissue, and measures the elasticity characteristics of the living tissue from the propagation velocity. The elasticity analysis unit (30) measures the propagation velocity of the shear wave from a measurement signal obtained by using the reflected ultrasonic wave received by the tracking wave transmitting/receiving unit (16). A control unit (42) determines whether or not to measure the elastic characteristics again based on the unnecessary components contained in the measurement signal. When it is determined that the elastic characteristic is measured again, the ultrasonic diagnostic device (100) changes the acoustic characteristic of the push wave according to the unnecessary component, and measures the elastic characteristic again.
PROBLEM TO BE SOLVED: To obtain the subject gel useful as a base for releasing a medicine to a specific organ site by including a specific saturated fatty acid, etc., in a gel substance prepared by polymerizing a specified compound. SOLUTION: This gel is obtained by mutually polymerizing the same or different segmental compounds represented by the formula [X is H or methyl; R is H, a lower alkyl, mercapto, etc.; R1 is a lower alkyl; (m) and (n) are each an integer of 0-15] (acryloyl-L-proline, etc.) in the presence of an organic solvent, etc., according to a catalytic or an ionizing radiation polymerization method, adding the resultant polymer into an aqueous solution of a saturated fatty acid (lauric acid, etc.), stirring the prepared solution at 5-40 deg.C for 1-7 days and freeze-drying the resultant solution. A medicine can be contained in the gel to afford a small intestinal delivery system without decomposing and releasing the medicine in the stomach.
Chronic wasting disease (CWD) affects cervids in North America, Asia, and Scandinavia. CWD is unique in its efficient spread, partially because of contact with infectious prions shed in secreta. To assess temporal profiles of CWD prion shedding, we collected saliva, urine, and feces from white-tailed deer for 66 months after exposure to low oral doses of CWD-positive brain tissue or saliva. We analyzed prion seeding activity by using modified amyloid amplification assays incorporating iron oxide bead extraction, which improved CWD detection and reduced false positives. CWD prions were detected in feces, urine, and saliva as early as 6 months postinfection. More frequent and consistent shedding was observed in deer homozygous for glycine at prion protein gene codon 96 than in deer expressing alternate genotypes. Our findings demonstrate that improved amplification methods can be used to identify early antemortem CWD prion shedding, which might aid in disease surveillance of cervids.
The invention discloses a livestock traditional Chinese medicine composition having functions of nourishing, fattening, tonifying qi and nourishing blood. The composition comprises following components by weight: 10-30 parts of basket fern rhizome, 10-40 parts of fleece-flower root, 10-20 parts of malt, 10-20 parts of soybean, and 1-10 parts of iron-dextrin. The formulation of the composition is scientific and reasonable. The composition has the functions of nourishing, fattening, tonifying qi and nourishing blood. The composition is free of toxic and side effects and medicine residues, and is convenient to use and low in cost. The composition can be used for treating common emaciation, slow growth, and the like for livestock.
Malaria is a major global health problem affecting approximately 241 million people and causing more than 600 thousand deaths, according to the latest WHO estimates. In parallel non-communicable life style diseases increase globally, also in malaria-endemic areas. Surprisingly few studies have investigated possible associations between malaria and non-communicable diseases. Higher prevalence of asymptomatic malaria infection has been shown among individuals with type 2 diabetes in Ghana and the risk of malaria increased with poor glucose control. In a recent study on more than 900 adults with P. falciparum malaria in Sweden, comorbidities and especially diabetes, metabolic syndrome and obesity were associated with a 3-5 times increased risk of severe malaria . Interestingly, these associations were apparent also in African immigrants, a group otherwise recognized to be at reduced risk of severe malaria due to pre-existing immunity. Altered metabolism and chronic inflammatory state in individuals with obesity and diabetes might affect severe progression of malaria. Moreover, poor antibody responses have been observed in obese individuals vaccinated against viral and bacterial infections; and impaired antibody mediated immunity might also affect the risk of malaria.

The overall aim of this project is to investigate whether diabetes, obesity and the metabolic syndrome affects the risk of severe malaria in an endemic setting.

The study will be performed at the District Hospital Dschang and the Bafoussam Regional Hospital in Western Cameroon. Adults diagnosed with malaria at the two hospitals, both at the outpatient clinic and admitted to the hospital wards, will be invited to participate in the study. Informed consent is needed for inclusion. The participants will be clinically evaluated for diabetes and the metabolic syndrome according to International Diabetes Federation (IDF) criteria. In addition to lab parameters below, weight and height will be measured for body mass index (BMI). Severe malaria will be defined according to WHO criteria.

Malaria species and parasite density will be assessed by microscopy of blood films stained with Giemsa. Clinical chemistry will include a fasting plasma glucose, glycated haemoglobin (HBA1c), lipids, erythrocyte sedimentation rate (ESR), liver enzymes, bilirubin, creatinine and haemoglobinopathies such as sickle cell will be assessed. HIV test will be offered to all patients. For patients admitted to hospital, fasting plasma glucose, parasitaemia and insulin levels will be measured on a daily basis. Venous EDTA blood sample will be collected at admission and stored frozen as plasma and packed cells for later PCR confirmation.
The invention relates to a formula and a method for treating liver channel and heart channel two-tissue combined diseases with traditional Chinese medicines. The traditional Chinese medicine formula comprises the following components: 2g of mulberry leaves, 3g of cattle bile, 3g of mung bean, 3g of thalictrum foliolosum, 3g of Chinese violet, 3g of wild chrysanthemum, 3g of dried rehmanniae root, 1g of aconitum, 3g of caulis trachelospermi, 1g of cortex periplocae radicis, 3g of pilea notata, 3g of cinnamon, 1g of dichroa root, 3g of field thistle, 3g of hematoxylon, 3g of safflower, 3g of radix curcumae, 3g of tabasheer, 3g of amber, 3g of vine of multiflower knotweed, 3g of concha pteriae, 2g of antelope horn, 3g of mulberry fruit and 3g of tortoiseshell. The selected acupuncture points comprise the Dadun, Hangjian, Xiguan, Ququan, Zuwuli, Jimai, Zhangmen, Shaochong, Shenmen, Yinxi, Lingdao, Qingling and Jiquan. The auxiliary appliances comprise a foreign body discharge barrel, a medicine introduction barrel, an auxiliary barrel, an ozone generator, an ultrasonic generator for discharging the foreign body and the like. The auxiliary articles comprise purified water, mulberry leaves and glutinous rice root whiskers. The traditional Chinese medicine formula can treat liver channel and heart channel two-tissue combined diseases, and can be clinically applied.
The novel device (IVM media system), is designed to support nuclear maturation of immature oocytes recovered after minimal ovarian stimulation with no LH/hCG administration, and improve oocyte competence. This may result in development of a greater number of embryos to the blastocyst stage.

FSH is administered starting on cycle day 3 to stimulate follicle growth. When the leading follicle reaches 12-14 mm, egg retrieval will be scheduled. No hCG/LH trigger will be administered. Specially designed maturation media is used to collect and culture the immature eggs once recovered from the follicle. Once the eggs have matured in vitro, fertilization and embryo culture, vitrification and comprehensive chromosomal screening will be completed as per standard operating procedures.
The patient will receive standard care inside the hospital. After discharge the experimental group will receive extended care including text messages. Participants in this arm will be offered up to 30 text messages to help implement the quit plan discussed during the hospitalization. Patients motivated to quit in the next 30 days or that had already quit will receive 30 messages and patients unwilling to quit will receive 16 messages. The messages content follows the self efficacy theory.
Elderly patients over 65 years of age who underwent surgery for femoral fracture under spinal anesthesia. These patients underwent oscillometric intermittent (5 mins) noninvasive blood pressure monitoring during the surgical procedure and received intraoperative hemodynamic management based on a liberal fluid therapy protocol.
Macromastia is an excessive, rapid, or slow growth of breast tissue in 1 or both breasts. While macromastia represents a benign lesion, it may cause breast, shoulder, back, and neck pain, poor posture, infections, and loss of nipple sensation. The pathogenesis of macromastia or hypertrophy of mammary tissue remains poorly understood. The purpose of this study is to investigate the immunohistochemical expression of several hormone receptors that may potentially influence the growth of breast tissue in women with macromastia. Immunohistochemical studies performed on representative sections of breast tissue from 63 patients diagnosed with macromastia included estrogen receptor, progesterone receptor, androgen receptor (AR), prolactin receptor, growth hormone receptor, and vascular endothelial growth factor. The expression of each stain was evaluated separately in the glandular epithelium and adipose tissue and calculated as an H-score. We observed that AR expression in breast glandular and adipose tissue in women with macromastia was significantly lower than benign, nonhypertrophic breast tissue of a control group. Although the analyses were controlled for the age, the fact the mean age and hormonal status differed between the patients and the controls could have affected the results. Additional large studies will be required to further verify this finding and increase the knowledge about the etiology of this condition and then guide pharmacological treatment of juvenile and/or idiopathic gigantomastia.